Articles

MAP-kinase and JAK-STAT pathways dysregulation in plasmablastic lymphoma

Hematopathology Unit, Hospital Clínic of Barcelona, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid
Hematopathology Unit, Hospital Clínic of Barcelona, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid
Hematopathology Section, Laboratory of Pathology, National Cancer Institute, Bethesda
Hematopathology Section, Laboratory of Pathology, National Cancer Institute, Bethesda
Hematopathology Unit, Hospital Clínic of Barcelona, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid
Hematopathology Unit, Hospital Clínic of Barcelona, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid
Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver
Department of Clinical Pathology, Robert-Bosch-Krankenhaus, Stuttgart, and Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, and University of Tübingen
Department of Pathology, City of Hope National Medical Center, Duarte
Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha
Biometric Research Branch, Division of Cancer Diagnosis and Treatment, National Cancer Institute, National Institutes of Health, Bethesda, MD
Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver
Department of Pathology, City of Hope National Medical Center, Duarte
Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, Canada; Department of Medicine, University of British Columbia, Vancouver
Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN
Hematopathology Unit, Hospital Clínic of Barcelona, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona
Hematopathology Unit, Hospital Clínic of Barcelona, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid
Department of Clinical Pathology, Oregon Health and Science University, Oregon
Department of Immunology and Centre for Cancer Biomedicine, University of Oslo and Oslo University Hospital, Oslo
Lymphoid Malignancies Branch, Center for Cancer Research, National Institutes of Health, Bethesda
Institute of Pathology, University of Wuerzburg, Wuerzburg
Department of Laboratory Medicine and Pathology, Mayo Clinic Arizona, Phoenix
Department of Clinical Pathology, Robert-Bosch-Krankenhaus, Stuttgart, and Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, and University of Tübingen
Hematopathology Section, Laboratory of Pathology, National Cancer Institute, Bethesda
Hematopathology Unit, Hospital Clínic of Barcelona, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid
Hematopathology Unit, Hospital Clínic of Barcelona, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid
Haematologica Early view May 6, 2021 https://doi.org/10.3324/haematol.2020.271957